Logo wahanariau.com
  2. Israel

Israel

Index
Globenewswire

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Selasa, 29 September 2026 - 22:34:15 Wib
Globenewswire

Teva Releases Q3 2026 Aide Memoire

Kamis, 24 September 2026 - 22:18:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Kamis, 24 September 2026 - 22:17:25 Wib
Globenewswire

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Rabu, 16 September 2026 - 22:54:54 Wib
Globenewswire

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Senin, 14 September 2026 - 21:28:13 Wib
Globenewswire

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Kamis, 10 September 2026 - 22:48:27 Wib
Globenewswire

Teva Announces Launch of Offering of Senior Notes

Senin, 07 September 2026 - 23:13:42 Wib
Globenewswire

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Jumat, 04 September 2026 - 22:48:00 Wib
Globenewswire

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Rabu, 02 September 2026 - 21:48:55 Wib
Globenewswire

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

Rabu, 02 September 2026 - 21:39:07 Wib
Globenewswire

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Selasa, 01 September 2026 - 22:16:20 Wib
Globenewswire

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Ahad, 30 Agustus 2026 - 20:13:14 Wib
Globenewswire

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Rabu, 19 Agustus 2026 - 21:48:36 Wib
Globenewswire

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Selasa, 11 Agustus 2026 - 21:24:55 Wib
Globenewswire

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Rabu, 29 Juli 2026 - 20:52:00 Wib
Globenewswire

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Kamis, 09 Juli 2026 - 22:23:52 Wib
Globenewswire

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Selasa, 07 Juli 2026 - 21:38:30 Wib
Globenewswire

Teva Releases Q2 2026 Aide Memoire

Jumat, 19 Juni 2026 - 22:07:17 Wib
Globenewswire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jumat, 19 Juni 2026 - 22:06:43 Wib
Globenewswire

AI-Driven Revenue Optimisation Delivers Nearly $600 Million in Additional Profit for Travel Companies, Mize Data Reveals

Selasa, 16 Juni 2026 - 22:32:17 Wib
Globenewswire

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Kamis, 11 Juni 2026 - 20:02:08 Wib
Globenewswire

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Senin, 08 Juni 2026 - 21:02:23 Wib
Globenewswire

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Kamis, 04 Juni 2026 - 20:50:43 Wib
Globenewswire

Teva to Present at the Goldman Sachs Global Healthcare Conference

Selasa, 02 Juni 2026 - 19:10:43 Wib
Globenewswire

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Kamis, 21 Mei 2026 - 22:34:10 Wib